<DOC>
	<DOCNO>NCT00332488</DOCNO>
	<brief_summary>demonstrate efficacy inhale Technosphere/Insulin combination metformin versus combination metformin secretagogue</brief_summary>
	<brief_title>Efficacy Safety Prandial Inhalation Technosphere/Insulin Combination With Metformin Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Nonsmokers clinical diagnosis Type 2 diabetes mellitus &gt; or= 6 month Stable regimen metformin &gt; = 1000mg/day maximum tolerate dose ) secretagogue &lt; = 1/2 maximum manufacturerrecommended daily dose without dose adjustment within precede 6 wks . Fixed dose combination product metformin sulfonylurea acceptable long individual dose meet inclusion criterion HbA1c &gt; or= 7.5 % &lt; or= 11.0 % BMI &lt; = 40kg/m2 . FEV1 &gt; = 70 % , Total Lung capacity &gt; =80 % DLco &gt; or= 70 % Treatment type antidiabetic therapy , metformin &amp; secretagogues within precede 12 week Serum creatinine &gt; 1.4mg/dL female subject &gt; 1.5mg/dL male subject History chronic obstructive pulmonary disease , clinically proven asthma and/or clinically important pulmonary function test and/or radiologic finding Evidence serious complication diabetes ( e.g . autonomic neuropathy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>